Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aveo Pharmaceuticals (NQ: AVEO )

6.722 +0.162 (+2.47%)
Streaming Delayed Price Updated: 2:58 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 73,063
Open 6.560
Bid (Size) 6.720 (4)
Ask (Size) 6.740 (44)
Prev. Close 6.560
Today's Range 6.530 - 6.740
52wk Range 3.060 - 7.550
Shares Outstanding 34,373,995
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Looking Into AVEO Pharmaceuticals's Return On Capital Employed
AVEO Pharmaceuticals (NASDAQ:AVEO) brought in sales totaling $20.92 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 40.58%, resulting in a loss of $10.20... 
Via Benzinga
Recap: AVEO Pharmaceuticals Q1 Earnings
AVEO Pharmaceuticals (NASDAQ:AVEO) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga

Performance

YTD
+27.55%
+27.55%
1 Month
+65.16%
+65.16%
3 Month
+20.25%
+20.25%
6 Month
+39.75%
+39.75%
1 Year
+2.00%
+2.00%

More News

Read More
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Via Benzinga
Earnings Preview: AVEO Pharmaceuticals
Via Benzinga
AVEO Pharmaceuticals Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
38 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
68 Biggest Movers From Yesterday
Via Benzinga
AVEO Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
96 Biggest Movers From Yesterday
Via Benzinga
50 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Recap: AVEO Pharmaceuticals Q4 Earnings
Via Benzinga
Earnings Preview For AVEO Pharmaceuticals
Via Benzinga
Earnings Scheduled For March 14, 2022
Via Benzinga
Aveo Says Tivozanib Patients Up To 5X More Likely To Experience Long-Term PFS Vs. Nexavar In Kidney Cancer
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Via Benzinga
NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of NKT2152, a HIF2α Inhibitor, and FOTIVDA® (tivozanib) for the Treatment of Advanced Clear Cell Renal Cell Carcinoma
From NiKang Therapeutics Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer
From AVEO Oncology
Via Business Wire
AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
From AVEO Oncology
Via Business Wire
AVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update
From AVEO Oncology
Via Business Wire
AVEO Oncology to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021
From AVEO Oncology
Via Business Wire
AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by the U.S. FDA for the Treatment of Relapsed or Recurrent Head and Neck Squamous Cell Carcinoma
From AVEO Oncology
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.